...
首页> 外文期刊>European Journal of Pharmacology: An International Journal >IPP-1 controls Akt/CREB phosphorylation extension in A(2a) adenosine receptor signaling cascade in MIN6 pancreatic beta-cell line
【24h】

IPP-1 controls Akt/CREB phosphorylation extension in A(2a) adenosine receptor signaling cascade in MIN6 pancreatic beta-cell line

机译:IPP-1在MIN6胰腺β细胞系中控制AKT / CREB磷酸化延伸,在MIN6胰腺β-细胞系中的腺苷受体信号级联

获取原文
获取原文并翻译 | 示例

摘要

Signaling through A(2a) adenosine receptor specifically prevent pancreatic beta-cells (PBCs) loses under diabetogenic conditions. However, signaling mediators of this receptor in PBCs remained unidentified. Thus, we aimed to investigate the possible involvement of PKA/Akt/IPP-1/CREB pathway in MIN6 beta-cells. In addition, we investigated IPP-1 role in A(2a) receptor signaling pathway. The expression of A(2a) receptor in MIN6 cell line was evaluated by RT-PCR and its functionality confirmed by quantification of cAMP in response to the CGS 21680, an A(2a) receptor agonist. MTT and Brdu assays were used to evaluate cell viability and proliferation, respectively. PKA activity and insulin release were evaluated using ELISA methods. P-Akt/Akt, p-IPP-1/IPP-1, and p-CREB/CREB levels were assessed using western blotting. IPP-1 knock down assessments was performed using specific siRNA. Our result revealed that MIN6 cells express A(2a) receptor which actively increased cAMP levels (with EC50 = 2.41 mu M) and PKA activity. Activation of this receptor increased cell viability, proliferation and insulin release. Moreover, we mentioned A(2a) receptor stimulation increased p-Akt, p-IPP-1, and p-CREB levels in dose (max at 10 mu M of CGS 21680) and time (max at 30 min after CGS 21680 treatment) dependent manner. Interestingly, herein, we found in IPP-1 knocked down cells, A(2a) receptor failed to activate Akt and CREB. Altogether, we mentioned that in MIN6 cells A(2a) receptor increase cell viability, proliferation and insulin release through PKA/Akt/IPP-1/CREB signaling pathway. In addition, we conclude A(2a) receptor signaling through this pathway is dependent to activation of IPP-1.
机译:通过信令(2a)的腺苷受体特异防止胰腺β细胞(的PBC)糖尿病的条件下失去。然而,这种受体的PBC的信号介质仍然不明。因此,我们的目的是探讨PKA / AKT / IPP-1 / CREB途径在MIN6β细胞可能参与。另外,我们研究了在A(2a)的受体信号转导途径IPP-1的作用。 A(2a)的受体在MIN6细胞系中的表达通过RT-PCR评价和它的功能响应于所述CGS 21680,一个A(2a)的受体激动剂证实的cAMP的定量。 MTT和BrdU测定用于分别来评价细胞存活力和增殖。采用ELISA方法PKA活性和胰岛素释放进行了评价。 P-AKT / Akt信号,对IPP-1 / IPP-1和p-CREB ​​/ CREB水平用western印迹评估。 IPP-1击倒评估使用特定的siRNA进行。我们的结果表明,MIN6细胞表达A(2a)的受体,其积极提高cAMP水平(具有EC 50 = 2.41微米)和PKA活性。这种受体的激活提高细胞活力,增殖和胰岛素释放。此外,我们提及的(2a)的受体刺激增加的磷酸化Akt,在剂量对IPP-1和p-CREB水平(最大值在10微米CGS 21680的M)和时间(最大为30分钟CGS 21680处理后)依赖性。有趣的是,在本文中,我们发现在IPP-1敲低细胞中,A(2a)的受体未能激活Akt和CREB。总之,我们提到,在MIN6细胞A(2a)的受体增加细胞活力,增殖和通过PKA / AKT / IPP-1 / CREB胰岛素释放信号传导途径。另外,我们的结论A(2a)的受体信号通过该途径是依赖于IPP-1的激活。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号